Amaç: Bu araştırmanın temel amacı, fitoterapi kavramının tarihsel dönüşümünü, bilim haritalama tekniklerine göre incelemektir. Gereç ve Yöntemler: Veriler, 'Web of Science Core Collection' veri tabanından elde edilmiştir. CiteSpace ve SciMAT yazılımları ile 1990- 2019 yıllarına ait 1.326 makale analiz edilmiştir. SciMAT yazılımı ile 3 döneme (1990-1999, 2000-2009 ve 2010-2019) özgü stratejik diyagram ve stratejik gelişim haritası elde edilmiştir. CiteSpace yazılımında ise zaman haritası ve atıf patlaması yapan çalışmalar analiz edilmiştir. Bulgular: Fitoterapi alanında en fazla sayıda araştırma Brezilya (n=275), Almanya (n=220) ve İtalya (n=122) tarafından yapılmıştır. En fazla sayıda makale (n=122), 2017 yılında yayımlanmıştır. Stratejik diyagramlardan 1990-1999 döneminde 4 motor tema, 2000-2009 döneminde 6 motor tema, 2010-2019 döneminde ise 9 motor tema elde edilmiştir. Stratejik gelişim haritası açısından bakıldığında ise fitoterapi biliminin gelişiminin devam ettiği ve derinlik kazandığı görülmektedir. Atıf patlaması yapan 27 çalışma tespit edilmiştir. Zaman haritası analizinde ise anlamlı 3 büyük küme belirlenmiştir. Sonuç: Politika yapıcılar ve kaynak dağıtım kanalları, son dönem verilerine dayalı motor temalarına teşvik eden düzenlemeler yapabilir. Fitoterapi konusunda; stratejik diyagram, tematik gelişim haritalama ve tematik ağ diyagramları ile ortaya konulan bilimsel haritalamanın, konuya ilgi duyan tüm paydaşlar ve akademisyenler açısından incelemesi gereken önemli bir bilgi kaynağı olabileceği değerlendirilmektedir.
Anahtar Kelimeler: Fitoterapi; alternatif tıp; bilim haritalama
Objective: The main purpose of this research is to examine the historical transformation of the concept of phytotherapy with science mapping techniques. Material and Methods: The data were obtained from the Web of Science Core Collection database. 1,326 articles from 1990-2019 were analyzed with CiteSpace and SciMAT software. Strategic diagram and strategic development map specific to three periods (1990-1999, 2000-2009 and 2010-2019) were obtained with SciMAT software. In the CiteSpace software, the time map and citation explosion studies were analyzed. Results: The highest number of studies in phytotherapy field was done by Brazil (n=275), Germany (n=220) and Italy (n=122). The highest number of articles were published in 2017 (n=122). From the strategic diagrams, 4 motor themes in the 1990-1999 period, 6 motor themes in the 2000-2009 period and 9 motor themes in the 2010-2019 period were obtained. From the perspective of the strategic development map, it is seen that the development of phytotherapy science continues and gains depth. 27 studies that identified citation burst were identified. Three significant clusters were identified in the time map analysis. Conclusion: Policymakers and resource distribution channels can make arrangements to promote motor themes based on recent data. In phytotherapy; strategic mapping, thematic development mapping and thematic network diagrams are considered to be an important source of information for all interested stakeholders and academics.
Keywords: Phytotherapy; alternative medicine; science mapping
- Menin A. Henri Leclerc and the birth of modern phytotherapy. Eur J Integr Med. 2012;4:187.[Crossref]
- Falzon CC, Balabanova A. Phytotherapy: an introduction to herbal medicine. Prim Care. 2017;44(2):217-27.[Crossref] [PubMed]
- Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy: A Quick Reference to Herbal Medicine. 1st ed. Germany: Springer Science & Business Media; 2003. p.1-424.[Crossref]
- Gupta RC. Nutraceuticals: Efficacy, Safety and Toxicity. 1st ed. Amsterdam: Elsevier, Academic Press; 2016. p.1-1040.
- Odugbemi T. Outlines and Pictures of Medicinal Plants from Nigeria. 1st ed. Lagos, Nigeria: University of Lagos Press; 2008. p.1-283.
- Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011;12(1):122-32.[Crossref] [PubMed]
- Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res. 2000;33(2):179-89.[Crossref] [PubMed]
- Petkova V, Hadzhieva B, Nedialkov P. Phytotherapeutic approaches to treatment and prophylaxis in pediatric practice. Pharmacia. 2019;66(3):115-9.[Crossref]
- Nwabueze RN. Biotechnology and the Challenge of Property: Property Rights in Dead Bodies, Body Parts, and Genetic Information. 1st ed. An Ashgate Book, UK.: Routledge; 2016. p.1-392.[Crossref] [PMC]
- Hou W. Treating Autoimmune Disease with Chinese Medicine. 1st ed. London: Elsevier Health Sciences; 2009. p.1-320.
- Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.[Crossref] [PubMed] [PMC]
- Fürst R, Zündorf I. Evidence-based phytotherapy in Europe: Where do we stand? Planta Med. 2015;81(12-13):962-7.[Crossref] [PubMed]
- Herbal medicine market size and forecast, by product (tablets & capsules, powders, extracts), by ındication (digestive disorders, respiratory disorders, blood disorders), and trend analysis, 2014-2024. Industry Report. Hexa Research. 2017.[Link]
- Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I. Revisiting the ancient concept of botanical therapeutics. Nat Chem Biol. 2007;3(7):360-6.[Crossref] [PubMed]
- Noras M, Yousefi M, Kiani MA. Complementary and alternative medicine (CAM) use in pediatric disease: a short review. Int J Pediatr. 2013;1(2):45-9.[Link]
- Clements DS, Ring M, Shah A. Integrative Medicine, An Issue of Primary Care: Clinics in Office Practice. Primary care: clinics in office practice, Vol 44, No 2. 1st ed. Philadelphia, PA: Elsevier; 2017. p.203-377.[Crossref]
- Dutt B, Kumar S, Garg KC. Mapping of plant-based medicine research in China and India. Research Evaluation. 2009;18(1):51-9.[Crossref]
- Fu JY, Zhang X, Zhao YH, Chen DZ, Huang MH. Global performance of traditional Chinese medicine over three decades. Scientometrics. 2012;90(3):945-58.[Crossref]
- SciMAT. (Erişim tarihi: 15.12.2019)[Link]
- CiteSpace. (Erişim tarihi: 30.12.2019)[Link]
- Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29(4):231-40.[Crossref] [PubMed]
- Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280(18):1604-9.[Crossref] [PubMed]
- Buck AC. Phytotherapy for the prostate. Br J Urol. 1996;78(3):325-36.[Crossref] [PubMed]
- Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533-9.[Crossref] [PubMed]
- Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 2000;55(4):533-9.[Crossref] [PubMed]
- Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9(5):379-95.[Crossref] [PubMed]
- Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology. 1999;53(4):671-8.[Crossref] [PubMed]
- Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol. 2002;41(5):497-506.[Crossref] [PubMed]
- Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest. 1995;9:291-7.[Crossref]
- Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol. 1998;33(3):340-7.[Crossref] [PubMed]
- Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557-66.[Crossref] [PubMed]
- Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors. J Steroid Biochem Mol Biol. 1995;54(5-6):273-9.[Crossref] [PubMed]
- Grasso M, Montesano A, Buonaguidi A, Castelli M, Lania C, Rigatti P, et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol. 1995;48(1):97-103.[PubMed]
- Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, et al. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate. 1993;22(1):43-51.[Crossref] [PubMed]
- Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998;37(2):77-83.[Crossref] [PubMed]
- Pieroni A, Quave C, Nebel S, Heinrich M. Ethnopharmacy of the ethnic Albanians (Arbëreshë) of northern Basilicata, Italy. Fitoterapia. 2002;73(3):217-41.[Crossref] [PubMed]
- Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996;48(1):12-20.[Crossref] [PubMed]
- Antonio GD, Tesser CD, Moretti-Pires RO. [Phytotherapy in primary health care]. Rev Saude Publica. 2014;48(3):541-53.[Crossref] [PubMed] [PMC]
- Pieroni A, Quave CL. Traditional pharmacopoeias and medicines among Albanians and Italians in southern Italy: a comparison. J Ethnopharmacol. 2005;101(1-3):258-70.[Crossref] [PubMed]
- Scherrer AM, Motti R, Weckerle CS. Traditional plant use in the areas of Monte Vesole and Ascea, Cilento National Park (Campania, Southern Italy). J Ethnopharmacol. 2005;97(1):129-43.[Crossref] [PubMed]
- Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al; Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344-51.[Crossref] [PubMed] [PMC]
- Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999;40(4):232-41.[Crossref] [PubMed]
- Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol. 1997;80(3):427-32.[Crossref] [PubMed]
- Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. 1995;345(8964):1529-32.[Crossref] [PubMed]
- Pieroni A, Muenz H, Akbulut M, Başer KH, Durmuşkahya C. Traditional phytotherapy and trans-cultural pharmacy among Turkish migrants living in Cologne, Germany. J Ethnopharmacol. 2005;102(1):69-88.[Crossref] [PubMed]
- Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46(5):547-54.[Crossref] [PubMed]
- Pieroni A, Nebel S, Quave C, Münz H, Heinrich M. Ethnopharmacology of liakra: traditional weedy vegetables of the Arbëreshë of the Vulture area in southern Italy. J Ethnopharmacol. 2002;81(2):165-85.[Crossref] [PubMed]
- Greiner KA, Murray JL, Kallail KJ. Medical student interest in alternative medicine. J Altern Complement Med. 2000;6(3):231-4.[Crossref] [PubMed]
- Loh KP, Ghorab H, Clarke E, Conroy R, Barlow J. Medical students' knowledge, perceptions, and interest in complementary and alternative medicine. J Altern Complement Med. 2013;19(4):360-6.[Crossref] [PubMed]
- da Rosa C. Traditional medicine and complementary/alternative medicine in primary health care: The Brazilian experience. In: Capelli O, ed. Primary Care at a Glance - Hot Topics and New Insights. Books on Demand; 2012.[Crossref]
- De Natale A, Pollio A. Plants species in the folk medicine of Montecorvino Rovella (inland Campania, Italy). J Ethnopharmacol. 2007;109(2):295-303.[Crossref] [PubMed]
- Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 2000;3(4A):459-72.[Crossref] [PubMed]
- Sawyer D. Economic and social consequences of malaria in new colonization projects in Brazil. Soc Sci Med. 1993;37(9):1131-6.[Crossref] [PubMed]
- Arslan N. [Medical and aromatic plants]. Türkiye Tohumcular Birliği Dergisi. 2016;17(5):66-9.[Link]
- Nandhini S, Narayanan KB, Ilango K. Valeriana officinalis: a review of its traditional uses, phytochemistry and pharmacology. Asian J Pharm Clin Res. 2018;11(1):36-41.[Crossref]
- Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67(6):1281-3.[PubMed]
- Ryu YW, Lim SW, Kim JH, Ahn SH, Choi JD. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015;94(2):187-93.[Crossref] [PubMed]
- Robert GY. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammatory biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14(9):1470-4.[Crossref]
- Parildar H, Serter R, Yesilada E. Diabetes mellitus and phytotherapy in Turkey. J Pak Med Assoc. 2011;61(11):1116-20.[PubMed]
- Tepe B, Sokmen M, Akpulat HA, Sokmen A. In vitro antioxidant activities of the methanol extracts of five Allium species from Turkey. Food Chemistry. 2005;92(1):89-92.[Crossref]
- Web of Science. (Erişim tarihi: 15.12.2019)[Link]
.: İşlem Listesi